|
|
| (3 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT[[FMC regimen]] |
| {{SI}} {{CMG}}; {{AE}} {{AV}}
| |
| | |
| {{SK}}FCMR Regimen; R-FCM Regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone Regimen
| |
| | |
| ==Overview==
| |
| | |
| {{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] and [[rituximab]] used to treat indolent [[non-Hodgkin's lymphoma]] and relapsed or refractory [[mantle cell lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63463&ns=NCI_Thesaurus}}</ref>
| |
| | |
| | |
| ==Regimen==
| |
| | |
| | |
| {{chemo|F|Fludarabine}}
| |
| {{chemo|C|Cyclophosphamide}}
| |
| {{chemo|M|Mitoxantrone}}
| |
| ==Indications==
| |
| | |
| *Indolent [[non-Hodgkin's lymphoma]] and relapsed or refractory [[mantle cell lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63463&ns=NCI_Thesaurus}}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Chemotherapy regimens]]
| |